Adrian Woolfson | Executive Vice President, Research And Development
Sangamo Theraputics

Adrian Woolfson, Executive Vice President, Research And Development, Sangamo Theraputics

Adrian Woolfson, BM, BCh, PhD, has over a decade of biopharmaceutical industry experience in drug discovery, medical affairs and early and late stage clinical development. Most recently, he served as Chief Medical Officer at Nouscom AG, a genetic cancer vaccine biotechnology company based in Basel, Switzerland, where he led the development of the company’s off-the-shelf and personalized neoantigen vaccine and oncolytic virus strategy. Dr. Woolfson previously worked at Pfizer Inc. and Bristol-Myers Squibb. Dr. Woolfson completed post-graduate training in internal medicine at Addenbrooke’s Hospital Cambridge. He holds a BM BCh degree in Clinical Medicine from Oxford University and a PhD in molecular immunology from Cambridge University.

Appearances:



Conference Day 2 - Wednesday 1st April 2020 @ 09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
last published: 05/Dec/19 09:46 GMT

back to speakers